News >

Frontline Pembrolizumab Improves Survival in NSCLC Patients With High PD-L1 Expression

Jason M. Broderick
Published: Thursday, Jun 16, 2016

Roger M. Perlmutter, MD, PhD

Roger M. Perlmutter, MD, PhD

Frontline pembrolizumab (Keytruda) improved overall survival (OS) versus chemotherapy in non–small cell lung cancer (NSCLC) patients with high levels of PD-L1 expression, according to results from the phase III KEYNOTE-024 trial reported by Merck, the company developing the PD-1 inhibitor.

Garon EB, Rizvi N, Hu R, et al. Pembrolizumab for the treatment of non–small cell lung cancer. N Engl J Med. 2015;372:2018-2028.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication